KDELR2

ER lumen protein-retaining receptor 2 · P33947 · KDELR2 on Sugi Atlas →

0 patent compounds predicted against KDELR2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to KDELR2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Does Aldosterone Cause Hypertension by a Non-Renal Mechanism? PHASE4UNKNOWN
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes PHASE4UNKNOWN
GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma PHASE2/PHASE3COMPLETED
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy PHASE2COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity PHASE2RECRUITING
CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops PHASE2UNKNOWN
Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer PHASE2WITHDRAWN
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer PHASE2UNKNOWN
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC PHASE2COMPLETED
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients PHASE1UNKNOWN
Tamoxifen in Patients With Oesophageal Cancer PHASE1UNKNOWN
A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors PHASE1COMPLETED
Choline Effects - Pre-symptomatic AD PHASE1COMPLETED
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors PHASE1COMPLETED
PBA Use for Treatment of ATF6-/- Patients EARLY_PHASE1SUSPENDED
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer EARLY_PHASE1COMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
Immunological Profile and Clinical Characteristics of Children Diagnosed With Chronic Granulomatous Disease nanUNKNOWN
Fatty Acids Lipidome and Oxidative Stress in Liver Transplantation nanUNKNOWN
Preliminary Study for Identification of Calcium-Binding Proteins in the Serum in Various Metabolic Bone Disorders nanUNKNOWN
FESPET Study: Female EStrogen recePtor in Endometrial Cancer Treatment nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study) nanCOMPLETED
Association Between Luminal Bile Salt Content and Duodenal Mucosal Integrity in Functional Dyspepsia nanCOMPLETED
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas nanACTIVE_NOT_RECRUITING
Autophagy Bladder Cancer nanUNKNOWN
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside nanUNKNOWN
Study of Tissue Samples From Women Treated With Paclitaxel for Breast Cancer on Clinical Trial CALGB-9344 or CALGB-9741 nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a KDELR2 binder may also engage these)

ProteinNameSimilarity
Q2KJ37 1.000 Q2KJ37 →
Q5XHA2 1.000 Q5XHA2 →
Q6P257 1.000 Q6P257 →
Q6PEH1 1.000 Q6PEH1 →
Q6PFS5 1.000 Q6PFS5 →
KDELR1 ER lumen protein-retaining receptor 1 1.000 landscape →
Q66JF2 1.000 Q66JF2 →
Q09473 1.000 Q09473 →
Q9CQM2 1.000 Q9CQM2 →
P35402 1.000 P35402 →
Q8R1L4 1.000 Q8R1L4 →
Q5U305 1.000 Q5U305 →
Q5ZKX9 1.000 Q5ZKX9 →
Q7ZXS5 1.000 Q7ZXS5 →
Q99JH8 1.000 Q99JH8 →
P33946 1.000 P33946 →
Q569A6 1.000 Q569A6 →
O43731 0.999 O43731 →
Q68ES4 0.999 Q68ES4 →
Q9ZTN2 0.999 Q9ZTN2 →
Q6PAB8 0.998 Q6PAB8 →
Q611C8 0.998 Q611C8 →
O42580 0.997 O42580 →
Q8VWI1 0.997 Q8VWI1 →
P48583 0.997 P48583 →
O76767 0.994 O76767 →
Q76NM1 0.991 Q76NM1 →
O94270 0.990 O94270 →
P33948 0.990 P33948 →
Q86JE5 0.989 Q86JE5 →